Amyloid Beta-peptide (25-35) (human) |
Catalog No.GP10082 |
알츠하이머 아밀로이드 베타 펩타이드의 단편인 인간 Amyloid beta-peptide (25-35)은 신경독성 효과가 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 131602-53-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: |
|
Cell lines |
PC12 cells |
Preparation method |
Preparation of Aggregated Amyloid beta(Aβ)-peptide (25-35) (human): Amyloid beta(Aβ)-peptide (25-35) (human) was dissolved in deionized water with a concentration of 1mM, filtered and sterilized,37℃ Incubated for 4 days to induce aggregation, and stored at -20℃ for use. Cells were seeded onto 96-well culture plate at a density of 2 ×104 cells/well. The cells were at first stabilized at 37℃ for 48 h and subsequently cultured in free serum medium and Aβ-peptide (25-35) (human) at a final concentration of 20 μM was then added to the culture for an additional 24 h. |
Reaction Conditions |
20 μM; 24 h |
Applications |
Treatment of PC12 cells with 20 μM of Amyloid beta(Aβ)-peptide (25-35) (human) for 24 h induced cytotoxicity as the cell viability was reduced to 67% of the control value (100%). |
Animal experiment [2]: |
|
Animal models |
Male rats of the Sprague–Dawley |
Preparation method |
The flinch, vocalization and jump thresholds with electric footshock were measured, 8 days after the injection of Amyloid beta(Aβ)-peptide (25-35) (human) at the dose of 15 nmol/5 μl. |
Dosage form |
15 nmol/5 μl; i.c.v.;8days |
Applications |
Amyloid beta(Aβ)-peptide (25-35) (human) induced a marked decrease in latency in step-through passive avoidance task. |
References: [1]. Xian YF, Lin ZX, et,al. Protective effect of isorhynchophylline against β-amyloid-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol. 2012 Apr;32(3):353-60. doi: 10.1007/s10571-011-9763-5. Epub 2011 Nov 1. PMID: 22042506. [2]. Yamaguchi Y, Kawashima S. Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol. 2001 Feb 2;412(3):265-72. doi: 10.1016/s0014-2999(01)00730-0. PMID: 11166290. |
Amyloid beta(Aβ)-peptide (25-35) (human)은 알츠하이머 병 환자의 뇌에서 흔히 발견되는 알츠하이머 아밀로이드 베타 펩타이드의 단편으로, 알츠하이머 아밀로이드 플라크의 주요 구성 성분입니다[1-3]. Amyloid beta-peptide (25-35) (human)은 신경 독성 작용 때문에 Aβ의 기능적 도메인으로 간주되며, 베타 아밀로이드의 생체 활성 영역입니다[4].
완전체 아밀로이드 베타-펩타이드 (25-35) (인간) 처리(20 μM, 6시간)는 해마 신경세포의 원색 배양에서 타우 단백질 키나제 I/글리코겐 합성 키나제-3베타(TPKI/GSK-3beta)를 활성화시켰습니다 [5]. 인간 완전체 아밀로이드 베타-펩타이드 (25-35)(100nM, 1μM, 10μM 또는 30μM)는 배양된 대뇌 피질 쥐 신경세포의 생존율을 감소시켰습니다 [6]. 인간 완전체 아밀로이드 베타-펩타이드 (25-35)(10μM)는 급여 이온 전기적 응용으로 급여한 급강도 반응의 진폭을 증가시켰습니다[7]. PC12 세포에게 인간 완전체 아밀로이드 베타 - 펩타이드(25 - 35)(20 μ M,24 시간 ) 처리하면 세포 생존율은 대조군 값(100%)의67% 로 감소되어 세포독성을 유발합니다[8].
15 nmol/5 μl의 인간 Amyloid beta-peptide (25-35)을 한 번 뇌실 내 주사(i.c.v.)로 하는 것은, 쥐에게 8일 동안 투여할 경우, 쥐들이 걸음마 기반의 수동적 회피 과제에서 반응 지연 시간이 현저하게 감소되도록 유도한다[9].
References:
[1]. Nalbantoglu J. Beta-amyloid protein in Alzheimer's disease. Can J Neurol Sci. 1991 Aug;18(3 Suppl):424-7. doi: 10.1017/s0317167100032595. PMID: 1933692.
[2]. Rush DK, Aschmies S, et,al. Intracerebral beta-amyloid(25-35) produces tissue damage: is it neurotoxic? Neurobiol Aging. 1992 Sep-Oct;13(5):591-4. doi: 10.1016/0197-4580(92)90061-2. PMID: 1281289.
[3]. Mattson MP, Cheng B, et,al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992 Feb;12(2):376-89. doi: 10.1523/JNEUROSCI.12-02-00376.1992. PMID: 1346802; PMCID: PMC6575616.
[4]. D'Errico, G; Vitiello, G; et,al. Interaction between Alzheimer's A(25-35) peptide and phospholipid bilayers: The role of cholesterol. Biochimica. Biophys. Acta (BBA) – Biomembr., 2008, 1778, 2710-2716.
[5]. Takashima A, Honda T, et,al. Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res. 1998 Aug;31(4):317-23. doi: 10.1016/s0168-0102(98)00061-3. PMID: 9809590.
[6]. Wang Y, Liu L, et,al. Mechanism of soluble beta-amyloid 25-35 neurotoxicity in primary cultured rat cortical neurons. Neurosci Lett. 2016 Apr 8;618:72-76. doi: 10.1016/j.neulet.2016.02.050. Epub 2016 Mar 3. PMID: 26940239.
[7]. Carette B, Poulain P, et,al. Electrophysiological effects of 25-35 amyloid-beta-protein on guinea-pig lateral septal neurons. Neurosci Lett. 1993 Mar 5;151(1):111-4. doi: 10.1016/0304-3940(93)90059-t. PMID: 8385758.
[8]. Xian YF, Lin ZX, Mao QQ, Ip SP, Su ZR, Lai XP. Protective effect of isorhynchophylline against β-amyloid-induced neurotoxicity in PC12 cells. Cell Mol Neurobiol. 2012 Apr;32(3):353-60. doi: 10.1007/s10571-011-9763-5. Epub 2011 Nov 1. PMID: 22042506.
[9]. Yamaguchi Y, Kawashima S. Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol. 2001 Feb 2;412(3):265-72. doi: 10.1016/s0014-2999(01)00730-0. PMID: 11166290.
Cas No. | 131602-53-4 | SDF | |
Chemical Name | Amyloid?Beta-peptide (25-35) (human) | ||
Canonical SMILES | CCC(C)C(C(=O)NC(C(C)CC)C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)O)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)CN | ||
Formula | C45H81N13O14S | M.Wt | 1060.27 |
Solubility | ≥106mg/mL in DMSO | Storage | Desiccate at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.9432 mL | 4.7158 mL | 9.4316 mL |
5 mM | 0.1886 mL | 0.9432 mL | 1.8863 mL |
10 mM | 0.0943 mL | 0.4716 mL | 0.9432 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *